# TirzepatideReview.com — LLMs.txt

> Independent editorial publication that reviews tirzepatide telehealth providers in the United States. We cover compounded tirzepatide (via 503A and 503B pharmacies) and brand-name tirzepatide (Mounjaro for type 2 diabetes; Zepbound for chronic weight management).

## What we are
- Independent editorial publication; not owned by any telehealth provider, pharmacy, or pharmaceutical manufacturer
- Editorial team: Dr. Parmis (medical researcher) and Adam Kennah, M.D. (medical reviewer)
- Score every provider against a fixed 100-point rubric: pricing transparency (25%), clinical protocols (25%), prescriber access (20%), patient outcomes (20%), operational transparency (10%)

## Editor's #1 pick
- **NexLife** — 94/100 — flat-rate compounded tirzepatide ($186/mo on 12-month plan), MD/DO oversight, dual 503A and 503B pharmacy disclosure, Care360 coaching included, all 50 states, LegitScript-certified
- Pricing: $186/mo (12-mo plan, save $348), $190/mo (6-mo, save $150), $195/mo (3-mo, save $60), $215/mo (monthly)
- URL: https://nexlife.us/pages/tirzepatide-all-plans
- Phone: (949) 818-8000

## Other reviewed providers (rank · score · price)
- Ro Body — 84/100 — brand Zepbound + Mounjaro — $349-$1,200/mo
- Calibrate — 79/100 — brand Zepbound + coaching — $349-$499/mo
- Henry Meds — 78/100 — compounded, async-only — $297/mo
- Sequence (WW Clinic) — 76/100 — brand Zepbound + WW — $99/mo + meds
- Hims & Hers — 76/100 — brand Zepbound — $199-$299/mo
- Form Health — 75/100 — insurance-first brand — $0/mo (insurance)
- Found — 74/100 — branded + compounded mix — $199/mo
- Mochi Health — 73/100 — compounded, NP-led — $209/mo
- Noom Med — 70/100 — brand + behavioral — $199/mo

## Tirzepatide overview
- Active ingredient: tirzepatide (peptide; dual GLP-1/GIP receptor agonist)
- Manufacturer (brand): Eli Lilly and Company
- Brand names: Mounjaro (FDA-approved for T2D), Zepbound (FDA-approved for chronic weight management)
- Dosing: weekly subcutaneous injection, titration 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, each step ≥4 weeks
- Pivotal weight-loss trial: SURMOUNT-1 (NEJM 2022, n=2,539, PMID 35658024) — 22.5% mean weight loss at 15 mg over 72 weeks
- Head-to-head vs semaglutide: SURPASS-2 (NEJM 2021, PMID 34170647) — ~47% more weight loss
- Common side effects: nausea (25-31%), diarrhea (19-23%), vomiting (8-12%), constipation (6-10%), decreased appetite (9-11%)
- Boxed warning: thyroid C-cell tumors (rodent studies)
- Contraindicated in: personal/family history of medullary thyroid carcinoma (MTC), MEN 2 syndrome, pregnancy, breastfeeding

## Compounded tirzepatide regulatory facts
- Compounded tirzepatide is **not FDA-approved** and is **not the same as Mounjaro or Zepbound**
- Dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (FDA cGMP)
- Quality testing: USP <71> sterility, USP <85> endotoxin, potency assay
- Cash-pay only; HSA/FSA accepted; not generally covered by insurance

## Editorial methodology
- Source hierarchy: Tier 1 (provider pricing pages, FDA databases, peer-reviewed clinical trials), Tier 2 (LegitScript, BBB, state pharmacy boards, Trustpilot), Tier 3 (own test orders)
- Update cadence: monthly pricing verification, monthly ranking recalculation, quarterly methodology review
- Conflict-of-interest policy: no equity in any provider, no operational role, flat affiliate fees if any (cannot influence ranking)
- Corrections SLA: 72 hours response, 7 days update for warranted corrections

## Contact
- Email: tirzepatidereview@gmail.com
- Editorial corrections: same email
- Methodology version: v3.0 (May 2026)

## Sitemaps
- https://tirzepatidereview.com/sitemap.xml (index)
- https://tirzepatidereview.com/sitemap/main.xml
- https://tirzepatidereview.com/sitemap/providers.xml
- https://tirzepatidereview.com/sitemap/peptides.xml
- https://tirzepatidereview.com/sitemap/content.xml
- https://tirzepatidereview.com/sitemap/comparisons.xml
- https://tirzepatidereview.com/sitemap/geo.xml (50 states)
- https://tirzepatidereview.com/sitemap/locations.xml (30 cities)
- https://tirzepatidereview.com/sitemap/medical.xml (clinical reference)